Lantheus Holdings, Inc. filings document its radiopharmaceutical operating results, Nasdaq-listed common stock, governance and material corporate events. Form 8-K reports furnish quarterly and annual financial results, business updates, FDA-related disclosures for diagnostic and therapeutic radiopharmaceutical products, share repurchase authorization, and executive and board changes.
Proxy materials describe director elections, executive compensation, shareholder voting matters and equity incentive plan approvals. The filings also cover material modifications to security holder rights, Regulation FD disclosures and capital-structure details relevant to common stock issued by a public radiopharmaceutical company.
Lantheus Holdings, Inc. agreed to be acquired by Curium US Holdings LLC, with a merger subsidiary combining into Lantheus so that it becomes a wholly owned subsidiary of Curium. Each outstanding share of common stock will be converted into the right to receive $102.50 per share in cash plus one contractual CVR that can pay up to $12.00 per share in cash if specified commercial milestones are achieved in its Global Prostate Cancer Diagnostics, Global Neurology Diagnostics and Global DEFINITY franchises. If completed, Lantheus common stock will be delisted from the Nasdaq Global Market and deregistered under the Exchange Act.
Closing requires a majority stockholder vote, expiration or termination of HSR and other regulatory waiting periods, absence of legal prohibitions, accuracy of representations, covenant compliance and no continuing Material Adverse Effect for Lantheus. The transaction is not subject to a financing condition; Curium has obtained equity and debt commitments. Termination fees include $385 million or a $100 million regulatory fee payable by Curium in certain cases and a $228 million fee payable by Lantheus in others. The board also approved a $6.0 million transaction bonus pool, including $4.0 million for CEO Mary Anne Heino and $500,000 for Daniel M. Niedzwiecki, and amended executive severance letters to clarify treatment of converted PSUs and eligibility for 2026 bonuses following qualifying terminations.
Lantheus Holdings agreed to be acquired by Curium US Holdings in an all‑cash merger. Curium will pay $102.50 per share in cash at closing and issue non‑transferable contingent value rights (CVRs) for up to $12.00 per share tied to future commercial milestones, for maximum consideration of $114.50 per share and total transaction value of up to approximately $8.0 billion. The price represents a 38% premium to Lantheus’ unaffected 60‑day volume‑weighted average price, with additional premiums versus other trading benchmarks.
CVR milestones are based on achieving specified 2028‑2030 aggregate sales targets across Global Prostate Cancer Diagnostics, Global Neurology Diagnostics and the Global DEFINITY business; there is expressly no assurance any CVR payments will be made. The deal, unanimously approved by Lantheus’ board after a strategic review, is expected to close in the first half of 2027, financed with a mix of debt and equity and subject to shareholder and regulatory approvals. Lantheus will remain a public company until closing, has paused its CEO search, will not host its Q2 2026 earnings call and is suspending prior full‑year 2026 guidance.
Vanguard Portfolio Management reports beneficial ownership of Lantheus Holdings Inc common stock on a Schedule 13G. The filing states beneficial ownership of 3,300,293 shares, representing 5.06% of the class, as of June 30, 2026.
Vanguard has sole voting power over 61,822 shares and sole dispositive power over all 3,300,293 shares, with no shared voting or dispositive power. The position reflects securities over which Vanguard Portfolio Management LLC and certain affiliated entities exercise dispositive and/or voting authority, including Vanguard funds and other managed accounts. No other individual person's interest in these securities exceeds 5% of the class.
Lantheus Holdings, Inc. director Gerard Ber reported a small tax-related share disposition. On May 14, 2026, 381 shares of common stock were disposed of at $96.67 per share to satisfy a tax obligation by delivering shares rather than cash.
After this tax-withholding transaction, Ber directly held 27,118 shares of Lantheus common stock. This type of Form 4 event reflects administrative handling of taxes on equity compensation rather than an open-market sale decision.
Lantheus Holdings Executive Chair and CEO Mary Anne Heino reported routine equity activity involving company common stock. The only transactional entry shows 1,227 shares of common stock were disposed of as a tax-withholding disposition at $96.67 per share, meaning shares were withheld to satisfy tax obligations rather than sold in the open market.
After this event, Heino directly holds 321,897 shares of Lantheus Holdings common stock. She also has indirect ownership through several trusts, including 179,300 shares held by The Heino 2024 Family Trust, 8,618 shares held by the Heino Irrevocable Trust, and 78,153 shares held by The Mary Anne Fennell Heino Revocable Trust - 2018.
Lantheus Holdings director Julie McHugh received a stock grant of 4,137 shares of Common Stock. The shares were acquired as a grant or award at a stated price of $0.0000 per share, indicating compensation rather than an open-market purchase. After this award, she directly owns 30,099 shares of Lantheus Holdings common stock.
Morrow Phuong Khanh reported acquisition or exercise transactions in this Form 4 filing.
Lantheus Holdings, Inc. director Phuong Khanh Morrow received a grant of 4,137 shares of Common Stock on May 14, 2026 as a compensation-related award. The filing shows no purchase price for this grant, indicating it was awarded rather than bought in the market. After this transaction, Morrow directly holds 7,237 shares of Lantheus common stock.
Lantheus Holdings director Maeusli Heinz Christoph received a stock grant of 4,137 common shares as compensation. The shares were acquired at no cash cost per share and are held directly. After this award, Christoph beneficially owns 30,014 shares of Lantheus Holdings common stock.
LENO SAM R reported acquisition or exercise transactions in this Form 4 filing.
Lantheus Holdings director Sam R. Leno reported an equity award of 4,137 shares of common stock. The shares were granted at a price of $0.00 per share as a compensation-related award, not an open-market trade. Following this grant, his direct holdings increased to 67,246 common shares.
Pruden Gary J reported acquisition or exercise transactions in this Form 4 filing.
Lantheus Holdings director Gary J. Pruden reported an equity compensation grant on Common Stock. He received 4,137 shares as a grant or award at $0.00 per share, bringing his directly held stake to 6,674 shares.
In addition, the filing lists indirect holdings of Common Stock held through the Georgeane Pruden Revocable Trust with 8,449 shares and the Gary J. Pruden Revocable Trust with 14,613 shares as of the same date.